Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Broadhurst · SciRah

Researcher profile · Semantic Scholar

H. Broadhurst

Share profile

H. Broadhurst — researcher profile on SciRah

h-index: 14
Works: 23
Citations: 1,080

Most-cited papers

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
J. Mazuski, L. Gasink, J. Armstrong, H. Broadhurst +5 more
2016Clinical Infectious Diseases368 citations Open access
Semantic Scholar
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L. Paz-Ares, A. Spira, D. Raben, D. Planchard +17 more
2020Annals of Oncology207 citations Open access
Semantic Scholar
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
G. Stone, P. Newell, L. Gasink, H. Broadhurst +5 more
2018Journal of Antimicrobial Chemotherapy76 citations Open access
Semantic Scholar
Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years with Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial.
J. Bradley, E. Roilides, H. Broadhurst, Karen Cheng +8 more
2019The Pediatric Infectious Disease Journal58 citations Open access
Semantic Scholar
Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
J. Bradley, H. Broadhurst, Karen Cheng, M. Méndez +9 more
2019The Pediatric Infectious Disease Journal57 citations Open access
Semantic Scholar
Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)
D. Raben, A. Rimner, S. Senan, H. Broadhurst +3 more
2019International Journal of Radiation Oncology, Biology, Physics55 citations
Semantic Scholar
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
C. Faivre-Finn, D. Spigel, S. Senan, C. Langer +12 more
2020Lung Cancer49 citations Open access
Semantic Scholar
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial
Alison Luckey, Manica Balasegaram, L. Barbee, Teresa A. Batteiger +79 more
2025The Lancet32 citations Open access
Semantic Scholar
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
J. Vansteenkiste, J. Naidoo, C. Faivre-Finn, M. Özgüroğlu +12 more
2024JTO Clinical and Research Reports31 citations Open access
Semantic Scholar
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
J. Naidoo, J. Vansteenkiste, C. Faivre-Finn, M. Özgüroğlu +7 more
2022Lung Cancer29 citations Open access
Semantic Scholar
Safety Profile of Ceftazidime–Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme
Karen Cheng, P. Newell, J. Chow, H. Broadhurst +3 more
2020Drug Safety28 citations Open access
Semantic Scholar
Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa
W. Nichols, G. Stone, P. Newell, H. Broadhurst +6 more
2018Antimicrobial Agents and Chemotherapy28 citations Open access
Semantic Scholar
Abstract CT024: Durvalumab (D) + platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
Mingchao Xie, P. Chugh, H. Broadhurst, Zhongwu Lai +8 more
2022Cancer Research22 citations
Semantic Scholar
First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.
Yuanbin Chen, L. Paz-Ares, M. Dvorkin, D. Trukhin +16 more
2020Journal of Clinical Oncology15 citations
Semantic Scholar
LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
L. Paz-Ares, Yuh-Min Chen, N. Reinmuth, K. Hotta +16 more
2021Annals of Oncology12 citations Open access
Semantic Scholar
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
B. Besse, G. Castro, E. Felip, K. Politi +7 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
N. Reinmuth, M. Garassino, D. Trukhin, M. Hochmair +12 more
20216 citations Open access
Semantic Scholar
Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume.
T. Edeki, M. Kujacic, H. Broadhurst, Jianguo Li +1 more
2014British Journal of Clinical Pharmacology5 citations Open access
Semantic Scholar
Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).
J. Naidoo, J. Vansteenkiste, C. Faivre-Finn, M. Özgüroğlu +7 more
20201 citations
Semantic Scholar
Efficacy of Ceftazidime-Avibactam against Multi-Drug Resistant Enterobacteriaceae and Pseudomonas aeruginosa from the Phase 3 Clinical Trial Program
G. Stone, L. Gasink, P. Newell, H. Broadhurst +2 more
20161 citations Open access
Semantic Scholar
118P Impact of grade ≥2 pneumonitis (G2+ PNS) on patient reported outcomes (PROs) with durvalumab (D) after chemoradiotherapy (CRT) in unresectable stage III NSCLC
R. Hui, J. Naidoo, M. C. Garassino, H. Broadhurst +4 more
2022Annals of Oncology0 citations Open access
Semantic Scholar
Erstlinienbehandlung mit Durvalumab plus Platin-Etoposid beim ED-SCLC: Explorative Analysen basierend auf dem Ausmaß der Erkrankung in CASPIAN
Helge Bischoff, N. Reinmuth, M. Dvorkin, M. Garassino +15 more
2021Pneumologie0 citations Open access
Semantic Scholar
Abstract 18343: B-type Natriuretic Peptide (BNP) Levels Correlate With Indices of Left Ventricular Function and Predict Outcomes Following Transcatheter Aortic Valve Implantation (TAVI): A Cardiovascular Magnetic Resonance Imaging Study
A. Lindsay, R. Kanyal, Paramvir Sawhney, H. Broadhurst +6 more
20150 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Newell×7
Invite
P. Newell — researcher profile on SciRah
L. Paz-Ares×7
Invite
L. Paz-Ares — researcher profile on SciRah
M. Özgüroğlu×7
Invite
M. Özgüroğlu — researcher profile on SciRah
G. Stone×6
Invite
G. Stone — researcher profile on SciRah

×6

Invite

C. Faivre-Finn — researcher profile on SciRah

Katrina Yates×6

Invite

Katrina Yates — researcher profile on SciRah

Invite

R. Hui — researcher profile on SciRah

Invite

S. Antonia — researcher profile on SciRah

Angela Wardman×4

Invite

Angela Wardman — researcher profile on SciRah

Invite

M. Newton — researcher profile on SciRah

P. Thiyagarajah×4

Invite

P. Thiyagarajah — researcher profile on SciRah

Invite

L. Havel — researcher profile on SciRah